Magneto Thrombectomy Solutions

Executive Summary

Magneto Thrombectomy Solutions (MagTS) is an Israeli med-tech startup developing a proprietary dual-action thrombectomy catheter that combines ultra-flexible aspiration with an electric-field attraction mechanism to capture and remove blood clots. The platform targets acute pulmonary embolism and ischemic stroke, aiming to achieve rapid, vessel-preserving clot extraction without thrombolytics. This approach addresses limitations of current devices, including incomplete clot removal and vessel damage. Currently in preclinical/early clinical stages, MagTS has demonstrated promising results in benchtop and animal models. The company is preparing for first-in-human studies and actively seeking Series A funding. If successful, the MagTS catheter could offer a paradigm shift in treating life-threatening clots, reducing procedure times and improving outcomes. With a strong IP portfolio and experienced management, the company is positioned for regulatory advancement.

Upcoming Catalysts (preview)

• Q3 2026Completion of Preclinical GLP Toxicology Studies70% success
• Q4 2026Initiation of First-in-Human Clinical Trial for Pulmonary Embolism40% success
• Q3 2026Series A Financing Round50% success